Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has closed its acquisition of Emalex Biosciences for USD 700 million upfront, with up to USD 200 million in contingent commercial milestone payments for a total potential value to USD 900 million. The Israel-based company, which first announced the deal in April, acquires global rights to ecopipam, an NDA-ready selective dopamine D1 receptor antagonist targeting pediatric Tourette syndrome, reinforcing its stated 'Pivot to Growth' strategy through late-stage neuroscience assets.
The USD 700 million closing payment is guaranteed while the additional USD 200 million is contingent on commercialization and regulatory approval for ecopipam. Net sales-based royalties, at undisclosed rates, apply globally upon commercialization. A US NDA submission is anticipated in the second half of 2026, representing the near-term regulatory catalyst for the contingent payments. Emalex Biosciences was created by Chicago-based Paragon Biosciences, which supported the asset through clinical development and NDA compilation.
Ecopipam selectively blocks the dopamine D1 receptor, a mechanistic distinction from existing tic-disorder treatments, which predominantly target D2 receptors or act through broader dopamine depletion. D1 receptor hypersensitivity is hypothesized to contribute to the repetitive and compulsive behaviors characteristic of Tourette syndrome. In the Phase III randomized withdrawal study, ecopipam demonstrated statistically significant separation from placebo on time to relapse in pediatric patients who had stabilized on the drug (p = 0.0084); results were published in JAMA Neurology. The US FDA has granted ecopipam both Orphan Drug and Fast Track designations for pediatric Tourette syndrome. The most frequently reported adverse events were somnolence (10.2%), insomnia (7.4%), and anxiety (6.0%).